Figure 5

A full length survivin protein vaccine expands survivin specific CD4+ cells even in patients with a low survivin reactive precursor frequency. A-B. An adenoviral construct was used to infect autologous myeloma patient DCs which leads to expression of a full length mutant survivin protein. Patient CD4+CD25- T cell survivin reactive frequency was calculated by LDA before and after 12 day co-culture with DC:ad-ms. The survivin vaccine increases the frequency of survivin reactive CD4+ cells (A), and significant fold expansion of survivin reactive CD4+ cells was observed (B), (before expansion # of survivin reactive cells normalized to 1). Line = Mean, Box = 25%-75% CI, Whiskers = minimum and maximum, *p < 0.05 by non-parametric t-test. * = p < 0.05 by paired ratio t-test.